SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) -- Ignore unavailable to you. Want to Upgrade?


To: Stephen M. DeMoss who wrote (262)6/11/2002 7:37:22 PM
From: John McCarthy  Read Replies (1) | Respond to of 371
 
Steve -

fwiw - I lurk Idaho on Yahoo IMMU - if you don't you might
want to give him a shot for awhile ....

below is an EMail between him and Cindy ..... as to current
status if IMMU and trials .....

Cindy's reply
by: idahoranch 06/11/02 04:05 pm
Msg: 34798 of 34824

I've been out cutting firewood all day with my daughter, so I just got back in in time to see the carnage. Amazing. I haven't even had time to read today's posts yet.
I E-mailed Cindy with a question a minute ago and asked her if I could post the answer. Here was my question.

<<Cindy, we've had quite a downdraft in the stock price of late. Is there any negative events that have not yet been disclosed that might be adding to the downdraft? I recognize that the sector has been hit very hard, but we have certainly gotten more than our share the last few days. My question also includes LymphoCide, and if anything in that area might be cause for concern. >>

Here is her answer.

<< There is absolutely no change in the fundamentals. LymphoCide continues clinical progress according to expectations, without delay. Recently, we announced the development of a humanized CD20 antibody because we are so encouraged with the combination trial with our CD22 + rituximab. Additionally, we have added three more oncologists to our staff to continue our aggressive development of our pipeline. I believe we're a stronger Company now, than ever, with a strong balance sheet, low burn rate, potential for more licensing arrangements and a rich product pipeline. Now, if the market would only calm down...

Cindy

messages.yahoo.com

finally - I do not want to mislead you -

I am out of IMMU - so my perspective maybe different
than if I owned ...

nonetheless - I think IMMU's *stuff* will be approved
one day .....

John McCarthy